Moderna Inc mentioned on Thursday it had dosed the primary participant in a mid-to-late stage research testing its Covid-19 vaccine candidate in adolescents aged 12 to lower than 18.
The research is being performed in collaboration with the Biomedical Advanced Research and Development Authority (BARDA).
“Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year,” mentioned Chief Executive Officer Stéphane Bancel.
The information comes because the United States prepares to start distributing the primary doses of Covid-19 vaccines from each Moderna and rival Pfizer/BioNTech to adults, upon regulatory nod for emergency use.
A panel of outdoor advisers to the U.S. Food and Drug Administration will meet on Thursday to debate whether or not to advocate using Pfizer’s vaccine for individuals aged 16 and older. An analogous assembly of advisers to the FDA is scheduled for December 17 to debate Moderna’s vaccine.
Rival Pfizer can also be learning its vaccine candidate in members as younger as 12.
(This story has been printed from a wire company feed with out modifications to the textual content.)